Akari Therapeutics PLC (AKTX)
Akari Therapeutics PLC is a biotechnology company focused on oncology research and development. The company is associated with a Nasdaq-listed depositary receipt for its common stock. Its pipeline centers on next-generation antibody-drug conjugates designed to deliver cancer-killing payloads. The lead payload, PH1, is intended to disrupt spliceosome function and stimulate an immune response that may contribute to further tumor cell death. Akari’s main product candidate, AKTX-101, is a preclinical trop2-targeting ADC being developed for solid tumors, including lung, breast, colon, and prostate cancers. The company is also advancing additional payloads, PH5 and PH6, as well as AKTX-102, a bispecific ADC that uses PH1. Akari Therapeutics is headquartered in Boston, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AKTX
|
$15.62
|
63.4% Upside
|
Bargain
|
$28.39
|
197.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-0.7x
|
1.3x
|
—
|
18.659 M
|
16.623 M
|
3.8%
|
61.6%
|
-122.8
|
—
|
38.9%
|
